NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive | Zendy

Marianne Pavel | Zendy; Henning Jann | Zendy; Vikas Prasad | Zendy; Ignat Drozdov | Zendy; Irvin M. Modlin | Zendy; Mark Kidd | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive

Author(s) -

Marianne Pavel,

Henning Jann,

Vikas Prasad,

Ignat Drozdov,

Irvin M. Modlin,

Mark Kidd

Publication year - 2016

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000446025

Subject(s) - hazard ratio , medicine , proportional hazards model , chromogranin a , confidence interval , gastroenterology , stage (stratigraphy) , neuroendocrine tumors , oncology , immunohistochemistry , biology , paleontology

A key issue in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is early identification and prediction of disease progression. Clinical evaluation and imaging are limited due to the lack of sensitivity and disease indolence. We assessed the NETest as a predictive and prognostic marker of progression in a long-term follow-up study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research